VanEck Pharmaceutical ETF
49 hedge funds and large institutions have $206M invested in VanEck Pharmaceutical ETF in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
7.66% more ownership
Funds ownership: 94.95% → 102.62% (+7.7%)
38% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 13
Holders
49
Holding in Top 10
–
Calls
$2.61M
Puts
$1.76M
Top Buyers
| 1 | +$68.3M | |
| 2 | +$36.4M | |
| 3 | +$4.45M | |
| 4 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$861K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$745K |
Top Sellers
| 1 | -$48.3M | |
| 2 | -$9.04M | |
| 3 | -$5.74M | |
| 4 |
Goldman Sachs
New York
|
-$1.21M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.09M |